Т	Title: Provider-led community Antiretroviral Therapy distribution in Malawi: Retrospective
2	cohort study of retention, viral load suppression, and costs.
3	John Songo¹, Hannah Whitehead², Brooke Nichols³, Amos Makwaya¹, Joseph Njala¹, Sam
4	Phiri <sup>1,4</sup> , Risa M. Hoffman <sup>2</sup> , Kathryn Dovel <sup>2</sup> Khumbo Phiri <sup>1</sup> , Joep J. van Oosterhout <sup>1,2</sup>
5	Affiliations
6	<sup>1</sup> Partners in Hope, Lilongwe, Malawi;
7	<sup>2</sup> Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine,
8	UCLA, Los Angeles, California, USA;
9	<sup>3</sup> FIND, Geneva, Switzerland.
10	<sup>4</sup> Department of Public Health and Family Medicine, Kamuzu University of Health Sciences,
11	Lilongwe, Malawi
12	
13	Corresponding Author: John Songo
14	Email: pemphosongo@gmail.com
15	

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

**Abstract** Background: Outcomes of community antiretroviral therapy (ART) distribution (CAD), in which provider-led ART teams deliver integrated HIV services at health posts in communities, have been mixed in sub-Saharan African countries. CAD outcomes and costs relative to facility-based care have not been reported from Malawi. Methods: We performed a retrospective cohort study in two Malawian districts (Lilongwe and Chikwawa districts), comparing CAD with facility-based ART care. We selected an equal number of clients in CAD and facility-based care who were aged >13 years, had an undetectable viral load (VL) result in the last year and were stable on first-line ART for ≥1 year. We compared retention in care (alive and no period of ≥60 days without ART) using Kaplan-Meier survival analysis and Cox regression and maintenance of VL suppression (<1,000 copies/mL) during follow-up using logistic regression. We also compared costs (in US\$) from the health system and client perspectives for the two models of care. Data were collected in October and November 2020. Results: 700 ART clients (350 CAD, 350 facility-based) were included. The median age was 43 years (IQR 36-51), median duration on ART was 7 years (IQR 4-9), and 75% were female. Retention in care did not differ significantly between clients in CAD (89.4% retained) and facility-based care (89.3%), p=0.95. No significant difference in maintenance of VL suppression were observed between CAD and facility-based care (aOR: 1.24, 95% CI: 0.47-3.20, p=0.70). CAD resulted in slightly higher health system costs than facility-based care: \$118/year vs. \$108/year per person accessing care; and \$133/year vs. \$122/year per person retained in care.

37 CAD decreased individual client costs compared to facility-based care: \$3.20/year vs.

\$11.40/year per person accessing care; and \$3.60/year vs. \$12.90/year per person retained in

39 care.

38

40

41

42

43

**Conclusion:** Clients in provider-led CAD care in Malawi had very good retention in care and VL

suppression outcomes, similar to clients receiving facility-based care. While health system costs

were somewhat higher with CAD, costs for clients were reduced substantially. More research is

needed to understand the impact of other differentiated service delivery models on costs for

the health system and clients.

# Introduction

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Antiretroviral therapy (ART) coverage has expanded greatly in sub-Saharan Africa and Malawi over the past 20 years (1). The sharply risen number of ART clients has resulted in health system challenges such as long waiting times, insufficient staffing and limited space (2). Together with the need for more client-centered and tailored care, such challenges have inspired innovative ways of delivering care to clients, broadly referred to as differentiated service delivery (DSD) models (3). Provider-led and community-led Community ART Distribution (CAD) DSD models have been implemented in Sub-Saharan Africa since 2010 (4). In providerled CAD, a team of health care workers (HCWs) travels to small, community-based health posts to provide comprehensive HIV services, including dispensing ART refills, on scheduled days. In community-led CAD, ART clients form groups and one community member collects ART refills at the facility for the whole group (5). Compared to facility-based services, CAD brings HIV care closer to people's homes, thereby reducing travel time, travel costs and opportunity costs, which may improve adherence and facilitate retention in care (3,6). Despite widespread implementation of CAD across sub-Saharan Africa, evidence regarding its effectiveness and cost-effectiveness in improving retention and viral load (VL) suppression is limited, outcomes have varied and none have been reported from Malawi. An early systematic review of studies from sub-Saharan Africa suggested that retention in care is higher in providerand community-led CAD than in standard facility-based care (6), but two later randomized trials in Zimbabwe and Lesotho found that retention in care and VL suppression did not differ significantly between health facility-based care, community-led CAD, and provider-led CAD

(7,8). Compared to standard facility-based care, CAD models had higher health system cost per client retained in care at 12 months in Zambia (9).

Comparing retrospective cohort data from clients receiving provider-led CAD and clients receiving facility-based care, we sought to evaluate the impact of provider-led CAD services on retention and VL suppression in Malawi. We also assess differences in cost between provider-led CAD services and facility-based care from a health systems and individual client perspective.

# Methods

# Study setting

Partners In Hope (PIH) is a Malawian non-governmental organization that provides PEPFAR-funded support for HIV services in Malawi's National HIV program. PIH implements a provider-led CAD model for stable (suppressed VL <1,000 copies/mL and on first-line ART) individuals at 4 health facilities in Lilongwe (urban setting, n=2) and Chikwawa (rural setting, n=2) districts, with a total of 20 CAD outreach sites. Provider-led CAD follows a hub-and-spoke model where a team of HCWs travels once a month from the hub (a large health facility) to a spoke (a village-based health post). The team is generally led by a nurse or occasionally a clinical officer, and includes an HIV diagnostic assistant (HDA), Treatment Supporter, counsellor and driver. Once a quarter, a data clerk joins the team. Services provided at CAD spokes include ART refills, VL sample collection, HIV testing services, family planning, screening for non-communicable diseases, referral to community services and adherence assessment and counselling.

### Study design and data collection

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

We conducted a retrospective cohort study making use of routinely collected data from standard medical records of 700 ART clients receiving ART care through CAD or health facilitybased services. Data were collected in October-November 2020, from two 'hub' health facilities in Chikwawa and two in Lilongwe, and 20 associated CAD 'spoke' sites. We selected all the clients registered in CAD between January 2019 (when CAD implementation began) and June 2019, and collected data from their first visit through August 2020 to allow for 14 months of observation time. Clients can choose to be enrolled into provider-led CAD if they meet programmatic criteria: being stable on first-line ART for more than 12 months, registered at a hub site, ready to disclose HIV status to other members of the CAD spoke, undetectable result of the last VL test (within 12 months), and age 13 years or older. We then compiled a list of individuals receiving standard care at the four hub facilities ("controls"). The inclusion criteria for controls were the same as for CAD enrolment mentioned above, except for the disclosure criterion. The number of controls included for each hub was equal to the number of CAD clients enrolled from that hub facility's CAD spokes. We selected hub controls chronologically, starting with those who had visited the facility in January 2019, and proceeding until the required number of clients was reached. We extracted data on all recorded visits for 14 months after study entry from clients' individual ART master-cards. A 14-month period was used to be able to capture full 1-year outcomes, including defaulting, as defined below. Collected data included: demographic characteristics, ART initiation date, dates of all CAD/facility visits, results of annual routine VL tests, and standardized ART outcomes (default, transfer out, stopped ART, death). All data were collected

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

on Android tablets using the SurveyCTO electronic data collection platform. Additional VL test results were extracted from the National Laboratory Information Systems Management (LIMS) Database, if missing on ART master-cards. No personal identifiers were collected from the data sources and therefore all data were anonymized. Ethical approval for the study was obtained from the National Health Sciences Research Committee in Malawi (#1099). **Key study definitions** Adverse outcome: recorded to have died, defaulted or stopped ART during follow-up. For individuals with multiple adverse outcomes recorded, the earliest outcome was used for all analyses. For example, if a client had defaulted, then returned to care, and subsequently died, they were classified as having defaulted. Defaulted: per national guidelines, defaulting from care was defined as being overdue for an ART refill appointment and estimated to have run out of ARVs for 2 months or longer, based on the quantity of ARVs dispensed at the last visit (10). Viral load outcomes: VL results were categorized according to national HIV guidelines: high VL (≥1000 copies/ml); low level viremia (200-999 copies/mL); or suppressed VL (undetectable-199 copies/mL). For logistic regression analyses, we applied a commonly-used binary VL outcome: <1000 copies/mL and ≥1000 copies/mL (11). VL results were only included from samples taken at least 6 months and no more than 18 months after enrollment into CAD or from the first visit in the study period for controls. We extended the period for VL results from 14 to 18 months due to the infrequency of VL testing during the study period.

# Statistical analysis

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Descriptive statistics were generated for client characteristics and outcomes. We compared viral load outcomes between the two models of care using chi-square tests and logistic regression. We used Kaplan-Meier survival analysis methods to compare retention in care at CAD spokes versus hub facilities over the 14 months of follow-up. Each client started contributing person-time to the analysis from the day that they were in enrolled into CAD or the earliest day that they visited the hub facility between January 2019 and June 2019. Followup time of clients who transferred to another health facility and of those who remained in care at the end of the follow-up period was censored on their last recorded visit day within the 14 months follow up period. We used Cox regression to produce crude and adjusted hazard ratios (aHR) of experiencing an adverse outcome, adjusting for sex, age and district. Univariate analysis of the association between key outcome variables and the intervention were stratified by gender to take into account significant gender differences across the HIV care cascade in Malawi (12). We assessed the extent of missing data in the sample by key outcome variables and covariates (retention, VL suppression, sex, age and district). Only VL suppression had missing data (21%) but the missing data did not vary by arm of intervention (CAD/hub) (p= 0.09). All observations with missing data on VL suppression were excluded from the analysis on VL suppression. All analyses were conducted with Stata v17 (Stata Corp., Texas, USA).

### Cost analysis

We calculated the cost per person retained for both facility-based care and CAD care from a health systems and individual client perspective.

Table 1 describes the unit costs collected locally or derived from the literature for both the cost to the health system and the cost to the client. For health systems cost per CAD spoke clinic day, we include all additional activities required to successfully implement a CAD visit, including use of a vehicle to and from the CAD (average of 32km round-trip per CAD visit), and the cost of a day of the full clinical team's services. The total costs were divided by the number of visiting clients to each CAD included in the study to determine the cost per individual client CAD visit.

#### **Table 1** Unit costs included in analysis

Variable	Unit cost (USD) 2022	Sources
Provider costs		
Hub clinic visit	\$2.90	(13)
CAD spoke visit	\$5.95	Program implementation data (2022)
ART day (first-line)	\$0.21	(13)
Viral load	\$14.2	(13)
Cost to client		
Wage lost for hub facility visit*	\$2.50	In-country information
Wages lost for CAD spoke visit**	\$0.625	In-country information

<sup>\*1</sup> day of minimum wage lost; \*\*0.25 day of minimum wage lost

## Results

# Sample characteristics at enrolment

We collected data on 700 ART clients, 350 from provider-led CAD and 350 from facility care (Table 2). Approximately 75% of both CAD and hub clients were female. Clients at CAD spokes were older (45.3 vs. 42.2 years) and had been on ART for longer (7.2 vs. 6.4 years).

Table 2. Characteristics of clients at enrollment in CAD spokes and at hub health facilities (controls)

Variable	Overall		CAD spok	es	Hub facilities		
Variable	n	%	n	%	n	%	
Total	700	100	350	50.0	350	50.0	
Age							
Median, years (IQR)	43.8 (36.5	- 51.4)	45.3 (38.3	3- 54.1)	42.2 (34.6	5- 49.4)	
13-24 years	27	3.9	10	2.8	17	4.9	
25-34 years	111	15.9	38	10.8	73	20.9	
35-44 years	246	35.1	123	35.1	123	35.1	
45-54 years	182	26.0	97	27.7	85	24.2	
55+ years	134	19.1	82	23.4	52	14.9	
Sex							
Male	178	25.4	87	24.9	91	26.0	
Female	522	74.6	263	75.1	259	74.0	
Duration on ART							
Median (IQR)	6.8 (4.1- 9	).7)	7.2 (4.2-	9.9)	6.4 (3.9-	9.3)	
<4year	171	24.4	81	23.1	90	25.7	
4-8years	251	35.9	119	34.0	132	37.7	
>8years	278	39.7	150	42.9	128	36.6	
District							
Lilongwe	228	32.6	114	32.6	114	32.6	
Chikwawa	472	67.4	236	67.4	236	67.4	

### Client outcomes

Descriptive outcomes at 14 months of follow up

At the end of the 14-months of follow-up, approximately 1% of participants had died, 10% had defaulted, and 5% had transferred to another health facility. Differences in standard client outcomes between CAD and facility-based care were minimal and not statistically significant, either overall or when stratified by sex (Table 3).

**Table 3** Client outcomes at 14 Months

	Males					Females									
	C.A	AD.	Н	ub			AD	Н	ub		C.	AD	H	ub	
Outcome	n	%	n	%	p-value	n	%	n	%	p-value	n	%	n	%	p-value
Died	4	1.1	3	0.9		3	3.4	2	2.2		1	0.4	1	0.4	
Stopped ART	0	0.0	0	0.0		0	0.0	0	0.0		0	0.0	0	0.0	
Defaulted	35	10.0	34	9.7	0.619	13	14.9	11	12.1	0.832	22	8.4	23	8.9	0.387
Transferred Out	12	3.4	19	5.4		4	4.6	3	3.3		8	3.0	16	6.2	
Alive on ART	299	85.4	294	84.0		67	77.0	75	82.4		232	88.2	219	84.6	
Total	350	100	350	100		87	100	91	100		263	100	259	100	

Kaplan-Meier survival estimates of retention in care at 14 months of follow up.

The average follow-up time was 11.6 months for clients at CAD spokes and 11.1 months at hub facilities. The cumulative probability of retention in care over the follow-up period was not significantly different between clients in provider-led CAD and facility-based HIV care (88.4% vs.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

88.3%; p-value 0.95) (Figure 1). Sex was the only covariate with a statistically significant impact on retention in the total study population (males 80.4% vs. females 90.8%; p =0.005) (Figure 2). Figure 1: Kaplan-Meier survival estimates of retention over 14 months of follow up by model of care Figure 2: Kaplan-Meier survival estimates of retention over 14 months of follow up by gender Controlling for sex, age, and district of residence, the risk of experiencing an adverse outcome was similar for clients in provider-led CAD and facility-based care (aHR: 1.05, 95%CI: 0.66-1.66, P-value: 0.80) **Viral load outcomes** VL test results were available for 553 clients, representing 79% of the overall sample (82% of CAD clients; 76% of hub clients; p= 0.09). In univariable analyses, standard VL outcomes were not significantly different between CAD and health facility-based care, whether overall or stratified by sex (Table 4). After adjusting for sex, duration on ART, age, and district of residence, there was no significant difference in prevalence of VL <1,000 copies/ml between clients in CAD (97%) and in hub care (96%): aOR 1.24, 95% CI 0.47-3.26, p-value 0.66.

#### **Table 4** Viral load suppression

	Overall						Males				Females				
	CAI	)	Н	ub		C.	AD	F	lub		C/	ΑD	Н	ub	
VL	n	%	n	%	p-value	n	%	n	%	p-value	n	%	n	%	p-value
≥1000 copies/ml	8	2.8	10	3.7		2	3.0	2	3.1		6	2.7	8	3.9	
200-999 copies/mL	57	20.0	40	14.9	0.260	14	21.2	7	10.8	0.264	43	19.6	33	16.3	0.552
undetectable-199 copies/mL	220	77.2	218	81.3		50	75.8	56	86.2		170	77.6	162	79.8	
Total	285	100	268	100		66	100	65	100		219	100	203	100	

#### Costs

196

197

198

199

200

201

202

204

205

206

207

208

Table 5 describes the resources used per client for both CAD-based and facility-based care.

Differences in resource use, considering the standard deviations, were small between the

models of care.

Table 5 Resource utilization of CAD-based care and facility-based care in Malawi (average and standard

# 203 deviation)

Variable	CAD-based care	Facility-based care
Number of clinic visits	0	4.6 (SD 1.4)
Number of CAD visits	5.1 (SD 1.5)	0
Number of ART days	351 (SD 92)	383 (SD 91)
Number of viral load tests	0.9 (SD 0.7)	1.0 (SD 0.6)

The total costs per person receiving care and the costs per person retained by model of care, from a health systems and individual client perspective, are described in Table 6. Health system cost estimates for provider-led CAD were \$118 per person receiving care per year and \$108 per person per year in facility-based care. Cost for individual clients was lower in provider-led CAD

(\$3.17 per person per year) than facility-based care (\$11.44 per person per year). In a second analysis limited to those retained in care, the gap in health systems costs between the two models of care was the same (\$10 lower in provider-led CAD), while differences in costs for clients widened slightly (from \$8.27 reduced cost per client to \$9.30 reduced cost for client retained in provider-led CAD).

Table 2. Cost per person in care and cost per person retained comparing facility- and provider-led CAD-(based on 2022 USD)

Variable	CAD	Facility-based care
Health system cost		
Cost per client	\$118 (SD \$29)	\$108 (SD \$24)
Cost per client retained	133	122
Client cost		
Cost per client	\$3.17 (SD \$0.96)	\$11.44 (SD \$3.53)
Cost per client retained	3.58	12.88

#### Discussion

In a retrospective assessment of two models of HIV care in Malawi, we found that retention in care and viral suppression outcomes were similar in provider-led CAD as compared to facility-based care. While health system cost per person provided care and per person retained in care were 9% higher in provider-led CAD, cost for 12-months of HIV care incurred by clients was 72% lower in CAD than in facility-based care.

Prior studies of CAD in sub-Saharan Africa had mixed findings. In two similar cluster randomized trials, one in Lesotho and one in Zimbabwe, no significant differences in retention in care and VL suppression were observed between facility-based 3-monthly ART (control), 3-monthly community ART groups, and 6-monthly provided-led CAD (7,8). In contrast, in a retrospective

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

cohort study from Mozambique, retention in care was significantly higher among clients in community-led CAD (at 99.1% at 12 months) than in facility-based care (89.5%, p<0.0001) (14). In the same setting, another retrospective cohort study found that individuals in facility-based care were more than twice as likely to be lost to follow up (HR 2.356; p = 0.04) than matched participants in community-led CAD (5). Differences in the organization of CAD services, variations in the local setting (including rural vs. urban) and the degree of donor support may explain these variations in ART outcomes. It has been suggested that in community-led CADs, clients acquire ownership of their ART care, as group representatives take turns to collect ART at the facility for the whole group and members actively trace group members who miss a group ART distribution session (14). Such activities may increase group members' ability to selfmanage their own care (15) and lead to better retention and VL suppression. To date, CADs are largely only available to stable ART clients and this presents potential missed opportunities to engage non-stable clients in CAD. From a health systems perspective, provider-led CAD is slightly more expensive than facilitybased care. The difference was relatively small (9% higher, or approximately \$10 more per person receiving care per year). Additional costs are due to HCWs traveling to CAD locations, but the vast majority of ART costs are generated by medication and VL testing, which do not vary by provider-led CAD or facility-based care. However, we found that provider-led CAD substantially reduced costs for clients by nearly three-quarters, mainly due to lower opportunity costs as clients need less travel time to access ART services. Health system costs of provider-led CAD can be reduced by decreasing the frequency of the team's travels to distribution sites, in combination with expansion of multi-month dispensing. This may also

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

further reduce clients' costs and could benefit retention and viral suppression outcomes (16). Our results are consistent with findings from the only other study from the region that assessed costs and outcomes across community-based ART models. In this study from Zambia, costs for CAD models ranged from an annual \$116/person to \$199/person compared with \$100/person for facility-care (9). A limitation of our cost analysis is that we did not incorporate travel costs for clients (cost of transportation to/from facility-based care) as many clients walk, use their own bicycle or make informal arrangements that are not directly tied to financial cost. It is therefore highly likely that we underestimated the difference in clients' costs and provider-led CAD may have a greater financial benefit to clients than reported here. This is supported by a qualitative study on client and nurse perspectives of provider-led community-based models of HIV care in Malawi, where clients reported that CAD services resulted in savings on transportation costs and the time it took them to travel to a health facility (17). As is common with observational studies, our results may be prone to bias as clients enrolled in CAD are selected based on specific characteristics, such as being clinically stable, which cannot be completely adjusted for in statistical analyses. However, great effort was put into ensuring that the eligibility criteria used for enrolment into CAD is adhered to during selection of controls through a strict study enrolment protocol that was double checked at data collection and at analysis. **Conclusions** 

Provider-led CAD services in Malawi had excellent one-year retention and VL suppression

financial costs to the health system but substantial savings for clients, which may benefit longer term engagement in care and ART outcomes. More study is need to determine cost-effectiveness of different DSD models in sub-Saharan Africa.

\*\*Acknowledgements.\*\*

We are grateful for funding by PEPFAR through USAID that allowed Partners in Hope to implement the provider-led CAD program and to collect the data for this analysis. We also thank the support of the participating health facilities and their management teams.

References

- Geneva: Joint United Nations Programme on HIV/AIDS. UNAIDS data 2021 [Internet].
   2021. Available from:
- https://www.unaids.org/sites/default/files/media\_asset/JC3032\_AIDS\_Data\_book\_2021 En.pdf
- 283 2. Kalua T, Tippett Barr BA, van Oosterhout JJ, Mbori-Ngacha D, Schouten EJ, Gupta S, et al. 284 Lessons Learned From Option B+ in the Evolution Toward "Test and Start" From Malawi,
- 285 Cameroon, and the United Republic of Tanzania. JAIDS J Acquir Immune Defic Syndr
- 286 [Internet]. 2017 May 1;75(1):S43–50. Available from:
- 287 http://insights.ovid.com/crossref?an=00126334-201705011-
- 288 00007%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/28398996
- 289 3. Davis N, Kanagat N, Sharer M, Eagan S, Pearson J, Amanyeiwe UU. Review of 290 differentiated approaches to antiretroviral therapy distribution. AIDS Care - Psychol
- 291 Socio-Medical Asp AIDS/HIV [Internet]. 2018;30(8):1010–6. Available from:
- 292 https://doi.org/10.1080/09540121.2018.1441970
- 293 4. Vogt F, Kalenga L, Lukela J, Salumu F, Diallo I, Nico E, et al. Brief Report: Decentralizing
- 294 ART Supply for Stable HIV Patients to Community-Based Distribution Centers: Program
- 295 Outcomes From an Urban Context in Kinshasa, DRC. JAIDS J Acquir Immune Defic Syndr
- 296 [Internet]. 2017 Mar 1;74(3):326–31. Available from:
- 297 https://journals.lww.com/00126334-201703010-00014
- 298 5. Jobarteh K, Shiraishi RW, Malimane I, Gudo PS, Decroo T, Auld AF, et al. Community ART
- support groups in Mozambique: The potential of patients as partners in care. PLoS One.
- 300 2016;11(12):1–14.
- 301 6. Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based
- antiretroviral therapy programs can overcome barriers to retention of patients and
- decongest health services in sub-Saharan Africa: a systematic review. Int Health
- 304 [Internet]. 2013 Sep 1;5(3):169–79. Available from:
- 305 https://academic.oup.com/inthealth/article-lookup/doi/10.1093/inthealth/iht016
- 306 7. Fatti G, Ngorima-Mabhena N, Mothibi E, Muzenda T, Choto R, Kasu T, et al. Outcomes of
- 307 Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV
- 308 Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe. J
- 309 Acquir Immune Defic Syndr. 2020;84(2):162–72.
- 310 8. Tukei BB, Fatti G, Tiam A, Ngorima-Mabhena N, Tukei VJ, Tshabalala I, et al. Twelve-
- 311 Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing
- of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized
- Noninferiority Trial. J Acquir Immune Defic Syndr. 2020;85(3):280–91.
- 314 9. Nichols BE, Cele R, Jamieson L, Long LC, Siwale Z, Banda P, et al. Community-based
- delivery of HIV treatment in Zambia: costs and outcomes. AIDS. 2021;35(2):299–306.

316 10. Malawi Ministry of Health. Clinical Management of HIV in Children and Adults. Lilongwe; 317 2018. 318 World Health Organization. Consolidated guidelines on HIV prevention, testing, 11. 319 treatment, service delivery and monitoring: recommendations for a public health 320 approach. Geneva; 2021. 321 12. United Nations Programme on HIV/aids. UNAIDS. UNAIDS data 2021 [Internet]. 2021. 322 Available from: 323 https://www.unaids.org/en/resources/documents/2021/2021 unaids data 324 13. Nichols BE, Offorjebe OA, Cele R, Shaba F, Balakasi K, Chivwara M, et al. Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. J Int AIDS 325 326 Soc [Internet]. 2020 Sep 9;23(9):e25612. Available from: 327 https://onlinelibrary.wiley.com/doi/10.1002/jia2.25612 328 14. Decroo T, Telfer B, Dores C Das, White RA, Santos N Dos, Mkwamba A, et al. Effect of 329 Community ART Groups on retention-in-care among patients on ART in Tete Province, 330 Mozambique: A cohort study. BMJ Open. 2017;7(8):1–9. 331 15. Dudhia R, Kagee A. Experiences of participating in an antiretroviral treatment adherence 332 club. Psychol Health Med [Internet]. 2015 May 19;20(4):488–94. Available from: http://www.tandfonline.com/doi/full/10.1080/13548506.2014.953962 333 334 16. Rasschaert F, Telfer B, Lessitala F, Decroo T, Remartinez D, Biot M, et al. A qualitative 335 assessment of a community antiretroviral therapy group model in Tete, Mozambique. 336 PLoS One. 2014;9(3):1–11. 337 17. Sande O, Burtscher D, Kathumba D, Tweya H, Phiri S, Gugsa S. Patient and nurse 338 perspectives of a nurse-led community-based model of HIV care delivery in Malawi: A 339 qualitative study. BMC Public Health. 2020;20(1):1-8.




Figure 1




Figure 2